TXN Target Analysis Report Summary
About the Target
Based on the provided context information, there are several key viewpoints regarding TXN (thioredoxin):
HDAC and mTOR inhibitors trigger oxidative stress and cell death by converging on antioxidant pathways and activating ASK1. Specifically, mTOR inhibitors suppress the glutathione pathway, while combined with HDAC inhibitors, they induce TXNIP expression through cooperative effects on chromatin and the MondoA-MLX transcriptional complex [6].
TXNIP inhibits the thioredoxin pathway, which is a major antioxidant pathway in tumors. This inhibition, along with ASK1 activation, leads to catastrophic oxidative stress, cell death, and tumor regression [6].
TXNIP ablation, G6PD overexpression, and ROS scavengers can prevent cell death, highlighting the role of TXNIP in regulating these processes [6].
ROS production during the development of red blood cells (RBCs) results in Keap1 oxidation, leading to the liberation of free Nrf2. This contributes to the upregulation of Prdx1 (peroxiredoxin 1) and Sod1 (superoxide dismutase 1) in RBCs. Upregulated Prdx1, together with Sod1 and Prdx2, plays a role in detoxifying ROS in the bloodstream [7].
Prdx1 associated with Trx1 (thioredoxin 1) leads to a decrease in apoptosis, thereby contributing to an increase in the lifespan of RBCs [7].
Overall, the combined findings suggest that the inhibition of the thioredoxin pathway by TXNIP, along with the activation of ASK1 and cooperative effects of HDAC and mTOR inhibitors, can induce oxidative stress, cell death, and tumor regression. In RBCs, the upregulation of Prdx1 and its association with Trx1 contribute to the detoxification of ROS and increased RBC lifespan [6][7].
Figure [1]
Figure [2]
Figure [3]
Figure [4]
Figure [5]
Figure [6]
Figure [7]
Note: If you are interested in the full version of this target analysis report, or if you'd like to learn how our AI-powered BDE-Chem can design therapeutic molecules to interact with the TXN target at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai.
More Common Targets
ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BECN1 | BRAF | BRCA1 | CAMP | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CD8A | CDH1 | CDKN1A | CDKN2A | CREB1 | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | EREG | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA4 | HSPA5 | IDO1 | IFNA1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MDM2 | MET | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SLTM | SMAD4 | SOD1 | SQSTM1 | SRC | STAT1 | STAT3 | STAT5A | TAK1 | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1
